Erythropoietin biosimilar - Pooyesh Darou

Drug Profile

Erythropoietin biosimilar - Pooyesh Darou

Latest Information Update: 20 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pooyesh Darou
  • Class Antianaemics; Erythropoietins
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 16 Oct 2017 Iran University of Medical Sciences, Mashhad University of Medical Sciences, Shiraz University of Medical Sciences, Tabriz University of Medical Sciences and Tehran University of Medical Sciences plan the phase III TONTT-2 trial for traumatic optic neuropathy (In children, In adolescents, In adults) in Iran (IV) (NCT03308448)
  • 23 Jul 2015 Pooyesh Darou completes enrolment in its phase I/II trial for Solid tumours in Iran (IRCT2015061822805N1)
  • 21 Apr 2014 Phase-I/II clinical trials in Solid tumours in Iran (SC) (IRCT2015061822805N1)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top